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ABSTRACT The motor protein myosin binds actin and ATP, producing work by causing relative translation of the proteins
while transducing ATP free energy. Smoothmusclemyosin has one of four heavy chains encodedby theMYH11 gene that differ at
the C-terminus and in the active site for ATPase due to alternate splicing. A seven-amino-acid active site insert in phasic muscle
myosin is absent from the tonic isoform. Fluorescence increase in the nucleotide sensitive tryptophan (NST) accompanies
nucleotide binding and hydrolysis in several myosin isoforms implying it results from a common origin within themotor. A wild-type
tonicmyosin (smA) construct of the enzymatic head domain (subfragment 1 or S1) has seven tryptophan residues and nucleotide-
induced ﬂuorescence enhancement like other myosins. Three smA mutants probe the molecular basis for the ﬂuorescence
enhancement. W5061 contains one tryptophan at position 506 homologous to the NST in other myosins. W506F has the native
tryptophans except phenylalanine replaces W506, and W5061(Y499F) is W5061 with phenylalanine replacing Y499. W5061
lacksnucleotide-inducedﬂuorescenceenhancement probably eliminatingW506as theNST.W506Fhas impairedATPaseactivity
but retains nucleotide-induced ﬂuorescence enhancement. Y499F replacement in W5061 partially rescues nucleotide sensitivity
demonstrating the role of Y499 as an NST facilitator. The exceptional response of W506 to active site conformation opens the
possibility that phasic and tonic isoforms differ in how inﬂuences from active site ATPase propagate through the protein network.
INTRODUCTION
Myosin is a molecular motor binding ATP and actin to pro-
duce work using ATP free energy transduction at the active
site to cause relative translation of the two proteins.
The multisubunit myosin is formed from a heavy chain
(MHC) and two smaller light chains called essential (ELC)
and regulatory (RLC). The MHC N-terminal globular head
contains the ATPase site, the actin binding site, and lever arm
where light chains bind. The lever arm swings during force
production to propel bound actin. The MHC C-terminus
forms a tail extending from the lever arm. The tail regulates
and participates in myosin self-assembly ﬁrst into dimers and
then a thick ﬁlament. The thick ﬁlament backbone is made
from associated myosin dimer tail domains with heads
projecting outward to permit interaction of the actin binding
site with adjacent actin (thin) ﬁlaments.
When phosphorylated, the RLC in smooth muscle triggers
actin-activated myosin ATPase activity and myosin-based
actin motility (1,2). Smooth muscle myosin contains one of
four smooth muscle MHCs encoded by the MYH11 gene (3).
The heavy-chain isoforms differ at the end of the tail near the
C-terminus and in the active site. The active site difference
consists of the seven amino acids QGPSFSY inserted or
omitted between Thr-211 and Gly-212 and has been shown
to correlate with tissue localization (4), enzyme kinetics (5–7),
but not the step length of the motor (6). MHCs lacking (smA)
or containing (smB) the insert are normally associated with
tonic or phasic smooth muscles, respectively. ELC is ex-
pressed in two isoforms in vivo (LC17a and LC17b) but had
no observed effect on in vitro myosin functionality (8). ELCs
exchanged into permeabilized smooth muscle gave evidence
for an isoform-speciﬁc effect on myosin functionality (9) but
other evidences, reviewed by Arner et al. (10), have shown
no correlation. Our work here investigating the nucleotide
sensitive tryptophan (NST) residue in myosin will utilize a
C-terminus truncated (short) human aorta smooth muscle
MHC eliminating both the C-terminus differences in the
smooth muscle isoforms and the RLC binding site. The ex-
pressed short human aorta smooth muscle myosin construct
resembles chymotryptic skeletal myosin subfragment 1 (S1)
in its length, monomeric associative state, and content of one
light chain (essential LC17a). Lacking RLC, this smooth
muscle myosin is persistently ‘‘switched on’’ for actin
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activation. The protein also lacks the seven-amino-acid
active site insert. We indicate our construct by smS1A.
The myosin ATPase cycle has intermediates maintaining
unique NST ﬂuorescence intensity levels providing an em-
pirical tool for characterizing kinetics that was exploited to
elucidate the myosin ATPase cycle (11,12). This cycle,
summarized by the following scheme,
M1ATP4M:ATP4M:ADP:Pi4
M
^
:ADP1 Pi4M1ADP1 Pi; (Scheme 1)
has intermediates M, M*, M**, and M^ corresponding to the
distinct myosin conformations. Work production occurs
during hydrolysis product release when the active site ‘‘back
door’’ opens to release product (13) and the motor lever arm
rotates to impel attached actin (14). In steady state, the
transient intermediates are occupied at fractional concentra-
tions that are known for a variety of myosins (12,15,16).
Nucleotide analogs induce static S1 structures imitating the
transient intermediate conformations permitting their inves-
tigation with low time resolution techniques such as x-ray
crystallography, CD, or steady-state ﬂuorescence. Exhaus-
tive study of the association of analog-induced and transient
intermediate S1 structures lead to the identiﬁcation of bound
ATPgS or trapped ADP.BeFx (low ionic strength) with
M*.ATP, trapped ADP.Vi or ADP:AlF4 or ADP.BeFx (high
ionic strength) with M**.ADP.Pi, and bound ADP with
M^.ADP (17–26).
Absorption dipole strength (27) and ﬂuorescence intensity
(28) increases are the consistently unequivocal response of
the highly conserved W506 in the myosin motor to nu-
cleotide binding and hydrolysis in the active site. This re-
sponse has been recorded in skeletal, cardiac, smooth muscle
(15), Dictyostelium discoideum (Dc) myosin II (29), and
probably other myosin isoforms implying it results from a
common structural origin within the function conserving
motor. Early work ruled out a tryptophan residue located at
the nucleotide binding site as the NST (30). The NST’s iden-
tity was later suggested to be W506 on the basis of circular
dichroism and ﬂuorescence experiments identifying the
peptide in myosin mobilized by ATP binding (31), Forster
energy transfer between a probe modifying a reactive thiol
(SH2) and tryptophan residues (32), by selective chemical
modiﬁcation of tryptophans (33), and by W506 emission
isolation using difference spectroscopy between native myo-
sin and a reactive thiol (SH1) modiﬁed version where W506
is selectively quenched (34,35). Much of the early work
on the NST utilized tissue puriﬁed skeletal muscle myosin.
Expressed myosins from Dc (29) and smooth muscle (36)
elegantly conﬁrmed NST identity as W506 and measured
homologous NST properties in these divergent myosin II
systems.
The notion of a common structural origin for Scheme 1
myosin energy transduction and NST ﬂuorescence intensity
modulation has motivated continued interest in W506 photo-
physics. Observation of NST dipole strength enhancement
upon nucleotide binding and hydrolysis in the active site
indicates at once that the effect perturbs the NST ground
state (37) normally suggesting signiﬁcant structural change.
The accompanying NST ﬂuorescence enhancement opens
the possibility for excited state processes usually involving
electron transfer (38,39) and/or solvent accessibility (40).
Yoshino et al. (41) suggested a direct interaction between
nucleotide and the NST indole as the mechanism for ab-
sorption enhancement in myosin that apparently conﬂicts
with modern myosin crystal structures unavailable at the time.
Bivin et al. (42) studied ﬂuorescence from model diketopi-
perazines incorporating tryptophan and various charged res-
idues and suggested local charged side chains modulate
emission from theW506 indole without a measurable ground
state effect. A Dc myosin motor domain mutant containing
one tryptophan at position 506 suggested both ground and
excited state mechanisms were in play (43). Tissue puriﬁed
skeletal myosin S1 containing ﬁve tryptophans was studied
with differential spectroscopy to isolate W506 absorption
and emission. The ﬂuorescence lifetimes and decay ampli-
tudes indicated that W506 forms a ground-state complex
with a static quencher inducing hypochromism in the tryp-
tophan absorption band. The highly conserved tyrosine,
Y499, was suggested as a likely static quencher (44,45).
Because WT smS1A has nucleotide-induced tryptophan
ﬂuorescence enhancement like other myosin isoforms we
constructed three smS1A mutants to probe its structural
basis. A tryptophan lite mutant, W5061, contains a single
tryptophan at position 506. A knockout mutant, W506F, has
phenylalanine at position 506 but retains the other six
tryptophans from the native protein. A mutant of W5061,
W5061(Y499F), has the conserved Y499 replaced with
phenylalanine. W5061 lacks nucleotide sensitive ﬂuores-
cence enhancement probably eliminating W506 as the NST.
W5061(Y499F) has partially rescued enhancement demon-
strating Y499’s ability to induce nucleotide sensitivity in
W506 as predicted (44,45). W506F retains nucleotide sen-
sitive ﬂuorescence enhancement despite signiﬁcant pertur-
bation of ATPase functionality. W5061(Y499F) also shows
a perturbed ATPase functionality common for side-chain
modiﬁcations in the vicinity of W506 (46,47).
Experimental results presented here, together with previ-
ous observations of NST ﬂuorescence enhancement in smB
isoforms, suggests that the smA and smB smooth muscle
myosin isoforms differ in how inﬂuences propagate from the
active site. The effect is apparent in the ability of W506 to
sense ATP hydrolysis only in the smB isoform. The seven-
amino-acid deletion from loop 1 in smA was previously
implicated in altered ATPase kinetics attributed to local in-
terference of the small loop 1 with ADP release. We demon-
strate here that the shortened loop 1 also affects distant sites
in the protein by measurably altering how information pro-
pagates from the active site. W506 sensitivity to nucleotide
binding and hydrolysis is observed in many myosin isoforms
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leading to its association with a conserved transduction mech-
anism in the motor. The present results open the possibility
that smA could differ from other isoforms in its transduction
mechanism.
METHODS
Chemicals
Ammonium sulfate, ATP, ADP, Na-Azide, dimethylformamide (DMF),
dithiothreitol (DTT), phenylmethylsulfonyl ﬂuoride (PMSF), N-acetyl-L-
tryptophanamide (NATA), and b-D(1) glucose are from Sigma (St. Louis,
MO). Phalloidin and pyrene iodoacetamide are fromMolecular Probes (Eugene,
OR). Bradford protein concentration assay is from Bio-Rad (Hercules, CA).
Leupeptin, chymostatin, and pepstatin are from Roche Applied Sciences
(Indianapolis, IN). Ni-NTA agarose was fromQiagen (Valencia, CA). Hexo-
kinase is fromWorthington Biochemical (Lakewood, NJ). All chemicals are
reagent grade or Ultra-Pure if available.
Cloning of human myosin heavy chain (MYH11)
and essential light chain (MYL6)
A potential full-length EST clone encoding MYH11 in SalI/NotI pCMV-
Sport 6 was obtained from American Type Culture Collection (ATCC) (No.
5182236). The clone was found to encode the entire catalytic and light-chain
binding domains of MYH11 smA variant, but was lacking the C-terminal
half of MYH11 due to truncation at an endogenous NotI site. The portion of
the clone encoding the catalytic and essential light-chain binding regions
(residues Met-1–Leu-813) was ampliﬁed by polymerase chain reaction
(PCR). A Kozak consensus sequence was incorporated into the forward
primer, and a 63 His encoding (plus stop codon) extension to immediately
follow Leu-813 was included on the reverse primer. A full-length clone
encoding human MYL6 isoform 1 in NotI/XhoI pBluescriptSK was ob-
tained from ATCC (No. 9322841). The full-length MYL6 isoform I was
ampliﬁed by PCR with a Kozak consensus sequence included in the forward
primer. Both PCR reactions were cloned into pCRBluntII Topo (Invitrogen,
Carlsbad, CA) and sequenced in their entirety.
Site-directed mutagenesis
We sequentially mutated six of the seven endogenous tryptophans in
pCRBluntII to phenylalanine or methionine using QuikChange Mutagenesis
(Stratagene, La Jolla, CA) to produce a mutant heavy chain 813 residues
long and containing a single tryptophan residue at position 506, W5061. In
the W5061 construct, W33, W37, W435, W591, and W619 were changed
to phenylalanine whereas W540 was changed to methionine. In the W506F
single-site mutant construct, W506 was changed to phenylalanine. Finally,
W5061(Y499F) was created from W5061 with Y499 changed to phenylala-
nine. Primers are listed in Table 1. Thewild-typeMYL6 (ELC),MYH11(1-813),
and three mutated MYH11(1-813) constructs were subcloned into vector
pVL1392 (Invitrogen). The accuracy of all constructs was veriﬁed by DNA
sequencing.
Protein expression and puriﬁcation
The baculovirus system was used to express wild-type and mutant constructs
by coinfecting Sf9 insect cells with a recombinant baculovirus encoding
WT-MYH11(1-813), W5061, W506F, or W5061(Y499F) and with a
baculovirus encoding the wild-type MYL6 (ELC). Equal titers of the heavy
and light chain encoded baculoviruses coinfected the Sf9 cells. Baculovi-
ruses were prepared for protein expression using the Bac-to-Bac system
(Invitrogen). Baculovirus stocks for heavy-chain and light-chain constructs
were made at Mayo or the Tissue Culture Core Facility, University of Col-
orado Cancer Center, UCHSC at Fitzsimons, Aurora, CO. Protein expres-
sions were carried out at both facilities.
Wild-type and mutant proteins were puriﬁed as described by Onishi et al.
(46) with modiﬁcations. Sf9 cells were lysed with hypotonic lysis buffer (20
mM Tris-HCl, pH 8.0, 4 mM MgCl2, 5 mM DTT, 1 mM PMSF, 1 mM
EGTA, 0.05 mg/ml leupeptin, 0.01 mg/ml chymostatin, and 0.01 mg/ml
pepstatin). To extract S1 protein, NaCl was added to 0.3 M and ATP was
added to 2 mM. The extract was fractionated with 34% and 70% ammonium
sulfate and then dialyzed for 4 h against 20 mM Tris-HCl, pH 7.5, 2 mM
MgCl2, 4 mM DTT, 0.2 mM PMSF, 0.2 M KCl, and 0.01 mg/ml leupeptin.
The dialyzed sample was incubated with 10% glucose and 20 units/ml of
hexokinase to remove residual ATP and then mixed with phalloidin sta-
bilized F-actin for 2 h at 4C. The actoS1 complex was collected via cen-
trifugation and dialyzed overnight against 20 mM Tris-HCl, pH 7.5, 2 mM
MgCl2, 7 mM 2-mercaptoethanol, 0.5 mM PMSF, 0.2 M KCl, 0.01 mg/ml
leupeptin, and 1 mM ATP. The actin was then dissociated from the S1 by
adding another 1 mM ATP. His-tagged S1 was further puriﬁed using Ni-
NTA agarose. On average, 1–2 mg of protein was puriﬁed from 1 3 109
cells. Protein purity ranged from 90 to 98%. Expressed protein samples are
shown in Fig. 1 using 12% SDS-PAGE. The eluted sample was treated with
5 mM EDTA to remove residual bound nucleotide and precipitated in a
dialysis solution of 25 mM TES, pH 7.0, 1 mM EDTA, 1 mM DTT, and
1 mg/ml leupeptin containing 75% ammonium sulfate. The precipitate was
collected via centrifugation and stored at20C for 2–3 months with no loss
of speciﬁc activity.
TABLE 1 Primers for generating MYH11 mutants
Primer Sequence (59–39)
W30F & W37F CCCAGTGGCCCAGGCTGACTTTGCCGCCAAGA-
GACTCGTCTTTGTCCCCTCGG
W435F ATATGAGCGCCTTTTCCGCTTTATACTCACCC
W540M GCTGGACGAGGAATGCATGTTCCCCAAAGCC
W591F GACTATAATGCGAGTGCCTTTCTGACCAAGAA-
TATGGACC
W619F GTTTGTGGCCGACCTGTTTAAGGACGTGGACC-
GCATCGTG
W506F GAGGGCATCGAGTTCAACTTCATCGAC
Y499F CATCCTGGAGCAGGAGGAGTTCCAGCGCGAG-
GGCATCGAG
FIGURE 1 Puriﬁed expressed WT,W5061, W5061(Y499F), andW506F
constructs containing MHC and ELC are shown as are standard molecular
weight proteins in 12% SDS-PAGE.
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Rabbit skeletal chymotryptic S1 was prepared according to Weeds and
Taylor (48). Skeletal actin was prepared from rabbit skeletal muscle acetone
dried powder according to Pardee and Spudich (49).
Protein concentration was estimated by using the Bradford assay with
bovine serum albumin as protein standard. Molecular mass was assumed to
the 115 kDa for smS1A.
Expressed protein sequencing by
mass spectrometry
Colloidal blue stained SDS-PAGE gel bands were reduced and alkylated
with DTT and iodoacetamide then digested with either endoproteinase Lys-
C (Wako Chemicals, Richmond, VA) or endoproteinase Asp-N (Roche
Applied Science, Indianapolis, IN). Extracted peptides were analyzed by
nano-ﬂow liquid chromatography tandem mass spectrometry (nanoLC-MS/
MS) using a ThermoFinnigan LTQ Orbitrap Hybrid Mass Spectrometer (50)
(ThermoElectron, Bremen, Germany) coupled to an Eksigent nanoLC-2D
HPLC system (Eksigent, Dublin, CA). The MS/MS raw data were searched
using SEQUEST (51) in ThermoElectron Bioworks 3.2 to correlate the
observed MS/MS fragment ions to theoretical fragment ions of all peptides
from the expected myosin mutated sequences. Searches were conducted
with ﬁxed cysteine modiﬁcations of 157 for carboxamidomethyl-cysteines
and variable modiﬁcations allowing 116 with methionines for methione
sulphoxide. Peptide mass search tolerances were set to 20 ppm and fragment
mass tolerance set to61.0 Da. The search was performed without specifying
an enzyme to conﬁrm that the acceptable high scoring peptides corresponded
to the appropriate Asp-N or Lys-C cleavage sites. All mutated peptide
matches gave Sequest Xcorr values .2.5 for z ¼ 2 precursor ions and were
within 1 ppm of the expected masses. The fragment ion matches were man-
ually inspected. The digests were also searched against the Swissprotein
database using the appropriate enzyme, with the same parameters to note the
matches from the wild-type sequence. No wild-type versions of the mutated
sequences were observed.
The mass spectrometry results conﬁrmed peptide sequences for W5061
and W5061(Y499F) mutant heavy-chain constructs. Mass spectrometry
was not performed on W506F.
ATPase and actin-activated ATPase assays
K1EDTA-ATPase activity was measured on samples at 37C in 250 ml
aliquots containing 0.35–0.70 mM expressed smS1A, 0.6 M KCl, 10 mM
EDTA, 25 mM Tris-HCl, pH 8.0, with 2 mM ATP. The Ca21ATPase assay
test solution was identical to that of K1EDTA-ATPase except 10 mM CaCl2
replaced the EDTA. Inorganic phosphate production from the ATPase
reaction was measured using the Fiske-Subbarow method (52).
Mg21ATPase and actin-activated Mg21ATPase activities were measured
at 25C in 220 ml aliquots containing 1 mM expressed smS1A, 60 mM KCl,
4 mM MgCl2, 1 mM EGTA, 1 mM DTT, 25 mM Tris-HCl, pH 7.6, with
1 mM ATP. Curves of Mg21 ATPase versus actin concentration, [A], were
evaluated with the equation V ¼ Vmax/(1 1 KM/[A]) to obtain the appar-
ent dissociation constant and maximum velocity, KM and Vmax. Baseline
Mg21ATPase activity at [A] ¼ 0 was subtracted from all data points.
Inorganic phosphate production from the ATPase reaction was measured
using the malachite green assay (53).
Pyrene labeled actin experiments
The actin binding assay used phalloidin stabilized pyrene iodoacetamide
labeled actin (54,55,55). Labeling efﬁciency was 96%. Myosin binding was
assessed using 0.2 mM actin in rigor or in the presence of 0.5 mM MgADP
as described previously (55–58). The ADP stock solution was pretreated
with 35 units hexokinase and 10% glucose to remove ATP impurities.
Measurements were done at 20C in 20 mM TES, pH 7.2, 0.1 M KCl, 2 mM
MgCl2, 1 mM DTT, and 1 mg/ml leupeptin. Binding constants were sur-
mised from myosin titration curves as described by Conibear and Geeves
(56). Reversibility of the actin binding was measured by adding 8 mM ATP
to the sample after completing the binding measurements; 85–90% of pyrene
ﬂuorescence intensity was recovered after ATP addition.
Spectroscopy measurements
Measuring buffer consisted of 0.45 M KCl, 20 mM Tris-HCl, pH 7.5, 2 mM
MgCl2, and 0.5 mM DTT. ADP or ATP bound states of WT, W5061,
W5061(Y499F), and W506F were formed by incubating the proteins at
concentrations of 0.8–8.0 mM in measuring buffer with 0.133 mM ADP or
0.1 mM ATP for 3 min at 20C. Apo-protein was treated identically but
without addition of nucleotide.
Trapped nucleotide analogs of smS1A were formed by incubating the
proteins at concentrations of 0.8–8.0 mM in measuring buffer with 5 mMKF
and 0.133 mM ADP for 3 min at 20C. BeCl2 (0.2 mM) or AlCl3 (0.2 mM)
were added and incubated at the same temperature for 30 min forming
ADP.BeFx-smS1A and ADP:AlF

4 -smS1A trapped complexes. Efﬁcient
trapping of W5061(Y499F) and W506F required use of 10 mM KF and 0.5
mM AlCl3. Stable complex formation was tested by measuring inhibition of
K1EDTA ATPase activity. Ca21ATPase was used to assess active site
trapping in W5061(Y499F) and W506F because these mutants have no
K1EDTA ATPase. Trapped smS1A had .90% ATPase inhibition.
Absorption spectra were measured on a Beckman DU650 (Beckman
Coulter, Fullerton, CA) or Cary 5E (Varian, Palo Alto, CA) at room tem-
perature. Differential protein absorption measurements detecting small
changes in tryptophan extinction were carried out on the Cary in 3-mm
pathlength rectangular cells and utilizing Apo or trapped ADP:AlF4 protein
at 2–4 mM concentration.
Circular dichroism (CD) spectra were recorded on a JASCO J715 at 8C
following the procedure described previously (59). The measurements were
carried out in 1–2 mm pathlength cells on Apo-protein at 6–8 mM con-
centration. CD spectra are plotted as extinction, De (60).
Steady-state and time-resolved tryptophan ﬂuorescence measurements
were performed with a PTI QuantaMaster spectroﬂuorometer (PTI, London,
Ontario, Canada) at 20C. Measurements were carried out in a 3-mm path-
length rectangular cell on protein samples with optical density ;0.05
(;0.12 mM protein and;0.13 mM nucleotide) for all wavelengths studied.
Protein samples included Apo, ADP or ATP bound, and, ADP.BeFx or
ADP:AlF4 trapped smS1A. Samples were illuminated with 298-nm wave-
length light suitable for selective excitation of tryptophan. Steady-state
measurements used an excitation bandwidth of 2 nm with emission collected
through a band-pass ﬁlter centered at 342 6 5 nm. Time-resolved mea-
surements were conducted using analog ﬂuorescence lifetime detection and
pulsed laser excitation. The 337–nm line from a pulsed nitrogen laser pumps
a dye laser containing rhodamine 590 (Exciton, Dayton, OH) with output
frequency-doubled to give 298-nm wavelength light. Emission was detected
at 340 nm with monochromator bandwidth of 8 nm.
The excitation pulse convoluted with detector response, the instrument
response function, is ;1.3 ns fullwidth at half-maximum. Observed time-
resolved ﬂuorescence intensity was ﬁtted by convoluting the instrument
response function with an exponential ﬁtting function,
FðtÞ ¼ +
p
i¼1
Aie
t=ti (1)
where Ai is the decay amplitude and ti the lifetime for the i
th component (61).
Best ﬁts were located using a nonlinear least-squares protocol.
We observed N-acetyl-L-tryptophanamide (NATA) to have a single 3.5-
ns lifetime in 0.1 M sodium phosphate pH 7 at 20C. The value obtained
with our instrument is somewhat longer than the 3.0-ns lifetime observed
previously (62). We veriﬁed that protein rotational relaxation does not make
a signiﬁcant contribution to ﬂuorescence intensity relaxation as shown
previously (44).
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Dynamic quenching of W506 steady-state ﬂuorescence, F, is heteroge-
neous with quencher accessible and inaccessible components. The Lehrer
equation,
F0
F0  F ¼
1
fKSV½Q1
1
f
(2)
is appropriate for this case where F0 is ﬂuorescence intensity in the absence
of quencher, KSV is the Stern-Volmer constant for the accessible component,
[Q] the quencher concentration, and f the fraction of total ﬂuorescence in-
tensity accessible to Q (40). Acrylamide quenching data is used to estimate
KSV and f by linear least-squares ﬁtting.
Steady-state pyrene-actin ﬂuorescence measurements were also per-
formed with the PTI spectroﬂuorometer. Samples were illuminated with
365-nm light and emission collected through a band-pass ﬁlter centered at
402 6 5 nm. Excitation monochromator bandwidth was 2 nm.
Homology modeling
Homology modeling was done with Modeller 8.2 (63) on the myosin heavy
chain (MHC) and ELC. Smooth muscle and skeletal myosin atomic
structures 1br1 (23) and 2mys (64) were the templates for the M** and M
conformations (see Scheme 1). Target sequences, consisting of the ﬁrst 812
residues from MHC (sequence identiﬁer gi13124879) and all 149 residues
from ELC (gi17986258) from the MYH11 gene, included both WT and
mutant sequences. Skeletal and smooth muscle MHC (gi13432175 and
gi3915778) and ELC (gi1942540 and gi5542589) targets were likewise
folded into the M and M** template for assessing modeling accuracy.
Homology model accuracy was evaluated using the DOPE score as
suggested in the Modeller 8.2 tutorial. The DOPE score is proportional to
potential energy per residue, smoothed over a 15-residue window, and
normalized by the number of restraints acting on each residue. It indicates
problem regions in the homology model when proﬁles are compared from
target and template sequences. Supplementary Fig. S1 A (see Supplementary
Material) compares DOPE proﬁles for skeletal, WT, and W5061 sequences
consisting of 961 residues from truncated MHC and ELC used in this study
and folded with the 2mys template. The skeletal sequence folded into the
skeletal template produces a DOPE proﬁle comparable to those for the
MYH11 sequences folded into the skeletal template for the entire peptide
suggesting MYH11 sequences are accurately folded. Supplementary Fig. S1
B (see Supplementary Material) shows results for the 1br1 template. The
latter has a higher sequence identity with MYH11 and more favorable DOPE
proﬁles for the native and mutant sequences. The single notable DOPE score
anomaly occurs with the skeletal template at AA525-527 (supplementary
Fig. S1 A) where smooth muscle myosin isoforms have a Pro-Asn-Asn insert
producing a kink in the switch II helix. The DOPE score at this position is
also elevated for the smooth muscle myosin template (supplementary Fig. S1
B) suggesting it is an intrinsic property of the sequence rather than a poorly
folded kink.
RESULTS
Myosin and actin-activated myosin ATPase
K1EDTA, Ca21, and Mg21 ATPases for the WT and mutant
smS1As are compared in Table 2. WT andW5061 K1EDTA,
Ca21, and Mg21 ATPases are comparable but slightly
inhibited in the mutant indicating undisturbed functional
performance in these tests. K1EDTA or Mg21 ATPases are
;95% inhibited or dramatically enhanced for W506F and
W5061(Y499F) compared to WT. Ca21 ATPase is dramat-
ically enhanced in the W506F mutant compared to WT.
Mg21 ATPase enhancement in W5061(Y499F) is identical
to that from actin activation of the WT protein. Similar
changes to the ATPases were observed for the smB isoform
with the W506F replacement (46) and in skeletal myosin
with covalent modiﬁcation of SH1 (65). W506, Y499, and
SH1 occupy the interface of the switch II helix (W506 and
Y499) and converter domain (SH1) where signiﬁcant con-
formation change occurs during energy transduction. The
residues are probably related by their common occupation of
a propagating conformation change pathway emanating from
the myosin active site (66) and by sensitivity to lever arm
movement.
Fig. 2 shows actin-activated Mg21ATPase data for WT
(solid square), W5061 (solid uptriangle), and W5061
(Y499F) (solid diamond) proteins. Table 2 summarizes KM
and Vmax computed from these data. Vmax decreases approx-
imately threefold, whereas KM is identical, for W5061
compared to WT. The W5061(Y499F) mutant Mg21
ATPase was not actin activated. These results parallel those
observed for the WT and mutant smB isoform (36,46).
Actin binding
Strong actin binding to smS1A was measured using
phalloidin stabilized, pyrene-labeled actin assay. Fig. 3 shows
pyrene-actin ﬂuorescence versus myosin head concentration
for W5061 in the Apo and ADP bound states. Fitted curves
provide the actomyosin binding constant. Binding constants
are listed in Table 3 for Apo and ADP states of WT,W5061,
and W5061(Y499F). All the smS1A binding constants are
TABLE 2 Myosin ATPases
ATPase (s1) Actin-activated Mg21 ATPase
Isoform K1EDTA Ca21 Mg21 Vmax (s
1) KM (mM)
WT 3.5 6 0.2 2.4 6 0.3 0.04 6 0.02 0.20 6 0.03 85.1 6 25.7
W5061 2.6 6 0.2 1.5 6 0.5 0.023 6 0.003 0.06 6 0.01 66.5 6 29.8
W5061(Y499F) 0.16 6 0.04 2.8 6 0.4 0.22 6 0.01 NA* NA*
W506F 0.18 6 0.01 9.5 6 0.4 0.41 6 0.01 NMy NMy
All uncertainties are mean 6 SE for n $ 3.
*Not activated.
yNot measured.
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larger than the rabbit Apo S1 binding constant of ;10
(mM)1 and fall into the order KApo(WT) » KApo(W5061).
KApo[W5061(Y499F)]. The picture is similar for the ADP
state with KADP(WT) . KADP(W5061) » KADP[W5061
(Y499F)] suggesting that the accumulated mutations weaken
strong actin binding. ADP decreases afﬁnity for actin in the
WT and mutant forms by two- to fourfold. Similar modest
decreases (approximately twofold) in actin binding afﬁnity
due to ADP were observed for nonmuscle cytoplasmic
myosin IIA (67) in contrast to the 5- to 60-fold decrease for
smB, cardiac, and skeletal myosin (68,69). Actin-activated
ATPase (Fig. 2 and Table 2) indicated actin binding in the
presence of ATP is identical for WT and W5061.
WT and mutant smS1A absorption and circular
dichroism spectroscopy
Fig. 4 (A) shows the steady-state extinction coefﬁcient spec-
trum, e, fromWT, W5061, and W5061(Y499F). Six excess
tryptophans in the WT protein shift extinction maximum to
the red as expected. Below 280 nm the tyrosine side-chain
absorption dominates. Tryptophan induced hypochromism
in the tyrosine contribution to the spectrum probably causes
the WT to fall below the W5061 spectrum despite their
identical tyrosine content. Alternatively, structural change
induced by the tryptophan substitutions in W5061 might
cause an increase in tyrosine extinction. The W5061
(Y499F) extinction spectrum detects the deletion of the ty-
rosine at AA499 with a slight decrease in extinction com-
pared to W5061 below ;280 nm.
Fig. 4 (B) is the difference extinction spectrum for the M**
and M conformations in WT, W5061, and W5061(Y499F).
The M** conformation was induced by active site trapping
with ADP:AlF4 : The data show that the absorption dipole
moment increases for the M** conformation compared to the
Apo form in the order WT . W5061(Y499F) . W5061.
The enhancement is quantitatively similar to observations
from native skeletal S1 (27,44) indicating nucleotide binding
and hydrolysis similarly perturbs W506 ground state interac-
tions in the two isoforms. The W5061 mutant has about half
the enhancement of the WT whereas the W5061(Y499F)
mutant is intermediate.
Fig. 4 (C) shows the steady-state CD extinction coef-
ﬁcient spectrum, De, from rabbit S1, WT, W5061, and
W5061(Y499F). Tryptophan near ultraviolet CD is
uniquely detected at wavelengths .295 nm. The rabbit S1
has a peak at 295 nm that is suppressed in the WT-smS1A
despite the six tryptophan residues present (compared to ﬁve
in the chymotryptic rabbit S1). Similar CD in the tryptophan
spectral region for the smA isoforms diverge at shorter
wavelengths where both tyrosine and tryptophan absorb.
FIGURE 2 Actin-activated Mg21ATPase for the WT (n), W5061 (:),
and W5061(Y499F) (¤) smA proteins. Error bars indicate mean 6 SE for
n $ 3. Dissociation constant, KM, and maximum ATPase velocity, Vmax,
tabulated from the data using V ¼ Vmax/(1 1 KM/[A]) are listed in Table 2.
FIGURE 3 Normalized pyrene labeled actin ﬂuorescence versus myosin
head concentration for W5061 in the Apo and ADP bound states. Fitted
curves provide the actomyosin binding constant. Binding constants are listed
in Table 3 for Apo and ADP states of WT, W5061, and W5061(Y499F).
TABLE 3 WT and mutant smS1A equilibrium actin
binding constants
K (mM)1
Isoform Apo ADP
WT 165 6 30 74 6 15
W5061 192 6 40 42 6 5
W5061(Y499F) 56 6 15 30 6 5
M1A4M.A and K ¼ [M.A]/([M][A]), for M and A myosin and actin, are
the binding scheme and equilibrium binding constant used to analyze data.
All uncertainties are mean 6 SE for n ¼ 5.
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WT and mutant smS1A
ﬂuorescence spectroscopy
Steady-state and time-resolved ﬂuorescence measurements
performed on the WT and mutant isoforms of the smS1A
investigated the effect of active site conformation on W506
ﬂuorescence intensity. Fig. 5 compares steady-state ﬂuores-
cence intensity increment, DI ¼ [F(nucleotide/analog) 
F(Apo)]/F(Apo), for ATP, ADP, and the trapped analogs
ADP.BeFx and ADP:AlF

4 : We ﬁnd that the incremental
ﬂuorescence response of W506 to active site conformation in
W5061 is negligible. The data show that it is improbable
that the highly conserved W506 is responsible for the WT
intensity increment unlike in the skeletal and smB myosins
(15,29). In contrast, Y499F replacement in W5061 sensi-
tizes W506 to nucleotide whereas W506F produces a modest
nucleotide-induced increment.
The highly conserved Y499 plays a role in how W506
responds to active site occupancy. In W5061 and W5061
(Y499F), W506 undergoes nucleotide-induced extinction
increase (Fig. 4 B) that is reduced by Y499. Thus the Y499
side chain affects W506 ground state to minimize (but not
eliminate) nucleotide-induced extinction enhancement.
Y499 further reduces ﬂuorescence enhancement by excited
state quenching to give no net ﬂuorescence increment in
W5061. In other myosin isoforms, where changing active
site conformation signiﬁcantly modulates W506 intensity,
Y499 is probably involved similarly except that the net effect
is W506 ﬂuorescence enhancement. Changing Y499 from a
nucleotide-induced net excited state quencher of W506
ﬂuorescence in smA to a net excited state enhancer of W506
ﬂuorescence in smB could be accomplished with a minor
relative side-chain conformation adjustment between W506
and Y499 much smaller than one probably imposed by
FIGURE 4 Spectra for smS1A WT, W5061, W5061
(Y499F), and rabbit skeletal S1. (A) Extinction coefﬁcient
spectra, e. (B) Extinction spectrum change upon active site
trapping with ADP:AlF4 : (C) CD extinction spectra, De.
FIGURE 5 The ﬂuorescence intensity increment, DI ¼ (F(nucleotide/
analog)  F(Apo))/F(Apo), for ATP, ADP (M^), and trapped nucleotide
analogs ADP.BeFx (M*) and ADP:AlF

4 : The WT (n), W5061 (:),
W5061(Y499F) (¤), and W506F (h) isoforms are depicted. The ATP
induced M** conformation was not observed with the W506F construct
because its high Mg21 ATPase prohibits the system from reaching steady
state with a predominant M** conformation. Error bars indicate mean SE for
n$ 9 ($7 for W506F). For W506F error bars are smaller than the size of the
open square symbol.
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primary sequence variation between the two isoforms. Sim-
ulations reported previously for the skeletal isoform suggest
Y499 is the only side-chain group signiﬁcantly modulating
W506 ﬂuorescence intensity by ground state interaction (44).
Backbone carbonyl groups are an important tryptophan ﬂuo-
rescence quencher in peptides (38) and are likely additional
important contributors to W506 intensity modulation.
The W506F nucleotide-induced ﬂuorescence enhance-
ment agrees qualitatively with the lack of enhancement in the
W5061 species. Quantitatively, W506F enhancement is be-
low that observed in WT. This ﬁnding is expected since the
homologous mutation in the Dc myosin II motor domain
shows the construct does not form the high enhancement
M** species in the presence of ATP (70). Thus the en-
hancement equivalence in WT M* and ADP:AlF4 trapped
W506F is due to the inability of W506F to form M**. A
similar effect is seen in the W5061(Y499F) construct where
nucleotide-induced ﬂuorescence enhancements shown in
Fig. 5 level off downstream of M*. Enhancements for ADP
bound and ADP.BeFx trapped W506F are also lower than in
WT. Structural differences between W506F and WT that
diminish tryptophan ﬂuorescence enhancement in W506F is
a possible rationalization. Signiﬁcant structural differences
between W506F or W5061(Y499F) on the one hand, and,
WT or W5061 on the other are indicated by perturbed
ATPases in the former (Table 2).
W506 ﬂuorescence intensity decay in W5061 is charac-
terized by two exponential functions A1exp(t/t1) 1
A2exp(t/t2) (Eq. 1) with amplitudes and lifetimes summa-
rized in Table 4 (top). Amplitudes are normalized by re-
quiring A1t11 A2t2¼1 for that Apo conformation. Lifetimes
fall into two groups containing the M and M^ (Apo and
ADP) on the one hand and M* and M** (ADPBeFx,
ADPAlF4 ; and ATP) conformations on the other. The latter
conformations have slightly shorter lifetimes.
W506 ﬂuorescence intensity decay in W5061(Y499F) is
likewise characterized by two exponential functions with am-
plitudes and lifetimes summarized in Table 4 (bottom).
Amplitudes are normalized like the W5061 mutant. Life-
times again partition into two groups containing M and M^
(Apo and ADP) on the one hand andM* andM** (ADPBeFx,
ADPAlF4 ; and ATP) on the other. In this case, M* and M**
conformations have much longer lifetimes. The data is con-
sistent with removal of an electron transfer partner from the
vicinity of W506.
W5061 acrylamide quenching
Acrylamide is a dynamic quencher of solvent accessible
tryptophans in myosin (34). Fig. 6 A shows the normalized
steady-state ﬂuorescence difference, DF ¼ (F0  F)/F0
where F0 is intensity without quencher, as a function of
acrylamide concentration for W5061. The apparently sat-
urable signal indicates W506 samples two environments,
one accessible and another inaccessible to solution borne
quencher. This is very different from skeletal muscle myosin
and the smB isoform of smooth muscle myosin where W506
ﬂuorescence does not have an inaccessible component
(34,36). Fig. 6 B indicates 1/DF for Apo and ATP bound
W5061 vs. 1/[Q] where, according to Eq. 2, the y-intercept
is 1/f and slope is 1/(fKSV). The data show the contrast
between the states where ATP bound protein has a homo-
geneously accessible W506 whereas nearly half of the ﬂuo-
rescence is inaccessible in the Apo form. Table 5 summarizes
Stern-Volmer constants and the accessible ﬂuorescence frac-
tions of W506 in the various myosin conformations. We see
that in the M** conformation (ATP and ADP:AlF4 ) all
W506 ﬂuorescence is accessible to acrylamide quenching.
This fraction decreases signiﬁcantly in the M and M* con-
formations with a minimum of ;0.6 in the M conformation.
The Apo form of the protein has highly heterogeneous tryp-
tophan ﬂuorescence and a large Stern-Volmer quenching
constant for the accessible portion of the tryptophan ﬂuo-
rescence. The ATP and ADP:AlF4 induced M** conforma-
tion is homogeneously accessible to tryptophan quenching
with a small Stern-Volmer constant. The ADP.BeFx induced
TABLE 4 W5061 and W5061(Y499F) time-resolved emission relaxation
Lifetime Amplitude
Active site Conformation t1 t2 A1 A2
W5061
Apo M 0.89 6 0.05 4.77 6 0.08 0.10 6 0.01 0.19 6 0.01
ADP M^ 1.25 6 0.24 4.89 6 0.12 0.09 6 0.01 0.18 6 0.01
ADP.BeFx M* 0.48 6 0.07 4.38 6 0.05 0.18 6 0.01 0.20 6 0.01
ADP:AlF4 M** 0.77 6 0.08 4.63 6 0.09 0.13 6 0.01 0.19 6 0.01
ATP M** 0.51 6 0.11 4.38 6 0.09 0.14 6 0.01 0.20 6 0.01
W5061(Y499F)
Apo M 1.75 6 0.04 5.26 6 0.03 0.11 6 0.02 0.15 6 0.01
ADP M^ 0.98 6 0.16 4.76 6 0.14 0.13 6 0.01 0.19 6 0.02
ADP.BeFx M* 2.05 6 0.02 6.13 6 0.02 0.15 6 0.02 0.12 6 0.01
ADP:AlF4 M** 2.34 6 0.06 6.61 6 0.14 0.21 6 0.01 0.09 6 0.01
ATP M** 2.31 6 0.07 6.32 6 0.12 0.14 6 0.03 0.11 6 0.01
All uncertainties are mean 6 SE for n $ 3.
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M* conformation has intermediate KSV and accessible
fraction.
Fluorescence lifetime data do not anticipate the heteroge-
neous acrylamide accessibility to W506. The shorter tryp-
tophan ﬂuorescence lifetime (Table 4) accounts for & 10%
of the total emission intensity in all states hence the longer
lifetime emits light from both environments detected by
acrylamide quenching. We attempted to partition the longer
lifetime component into two subcomponents but the curve
ﬁtting did not give interpretable results. Although acrylam-
ide quenching readily distinguishes two probe environments
in the majority ﬂuorescence emission, W506 lifetimes in
these two environments are not readily distinguished.
DISCUSSION
The protein matrix of atoms is a heterogeneous medium
propagating structure deformations that perform functional
time-ordered protein conformation change. In myosin, de-
formations are manifested as the ability of nucleotide binding
and hydrolysis at the active site to remotely affect lever arm
attitude and actin binding afﬁnity. Causal active site control
of remote sites follows from the observation that myosin
converts ATP to products during contractile movement
rather that contractile movement generating ATP from pro-
ducts. Hence, remote sites are linked by physical pathways
through the protein matrix and by causality, the time order-
ing of dependent events. We study some of these elements of
the transduction mechanism with experiments conducted on
a human tonic smooth muscle myosin construct.
Human tonic and phasic smooth muscle myosins differ by
a seven-amino-acid segment in loop 1 at the active site. The
loop 1 shortened by the deleted segment in the tonic smA
isoform alters myosin enzyme kinetics probably by inhibit-
ing product egress or substrate ingress (5–7,67). Homology
modeling of smA and smB isoforms conﬁrms that loop 1
structural heterogeneity is reduced in smA implying the
same for loop 1 ﬂexibility. However, experimental results
presented here argue that the differences induced by the
seven-amino-acid deletion goes beyond steric inhibition of
substrate to affect spatial aspects of propagating structure
deformation in the motor core.
The chief experimental evidence for a difference in trans-
duction mechanism between smA and smB is that the NST in
all tested myosins is W506 except, as we have shown, for the
human tonic smooth muscle myosin smA isoform. Absorp-
tion dipole strength and ﬂuorescence intensity increases in
the highly conserved W506 consistently accompany active
site nucleotide binding and hydrolysis in a variety of myosin
isoforms implying it results from a common structural origin
within the conserved protein core (27–29,31–36). How-
ever, the tryptophan lite construct (W5061) containing one
FIGURE 6 (A) Normalized steady-state ﬂuorescence intensity difference,
DF ¼ (F0  F)/F0 where F0 is intensity without quencher, as a function of
acrylamide concentration, [Q], for W5061. Error bars indicate mean 6 SE
for n ¼ 4. (B) Double reciprocal plot of acrylamide concentration versus DF
(see Eq. 2) for Apo and ATP boundW5061. The slope of the ﬁtted curves is
1/(f KSV) where f is the quencher accessible fraction and KSV the Stern-
Volmer constant. Insert is a close-up of the y-intercept equaling 1/f. Error
bars indicate mean 6 SE for n $ 2. Table 5 summarizes KSV and f of
W5061 in the various myosin conformations.
TABLE 5 Stern-Volmer constants and quenchable
ﬂuorescence fractions of W5061
Active site Conformation KSV f
Apo M 8.9 6 1.9 0.57 6 0.07 (4)
ADP.BeFx M* 6.5 6 1.3 0.67 6 0.11 (3)
ADP:AlF4 M** 4.8 6 0.6 0.94 6 0.21 (3)
ATP M** 2.7 6 1.3 1.14 6 0.36 (2)
All uncertainties are mean 6 SE for (n) experiments.
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tryptophan at position 506 has lowered nucleotide-induced
dipole strength enhancement (Fig. 4) and no ﬂuorescence
enhancement (Fig. 5). Fluorescence lifetimes are also little
affected by nucleotide in the active site (Table 4). W506
exposure to solution borne acrylamide changes measurably
upon nucleotide binding and hydrolysis in the active site
(Fig. 6) in a manner very different from that observed for
skeletal (34) and smooth muscle smB myosin (36). The
presence of a substantial acrylamide inaccessible fraction of
W506 ﬂuorescence, most pronounced in the apo-form of
smS1A, was not seen previously. Control experiments as-
sessed construct functionality by comparing with WT its
myosin ATPase (Table 2), actin-activated myosin ATPase
(Table 2), and strong binding to pyrene labeled actin (Fig. 3
and Table 3). W5061 shows nearly identical ATPase and
KM, but has an actin-activated ATPase Vmax ; 1/3 that of
WT. Its strong binding to actin in Apo and ADP conforma-
tions is very similar to the WT. The W5061 to WT char-
acteristics comparison parallels that of the homologous
tryptophan lite construct in smB (36,46). We found W5061
to be completely functional by these metrics.
The highly conserved Y499 was predicted to affect W506
spectroscopy in skeletal S1 based on ground state calcu-
lations from static myosin crystal structures (35,44). The
W5061(Y499F) mutant indicates Y499 affects W506 ab-
sorption (Fig. 4 B) and ﬂuorescence (see the W5061(Y499)
curve in Fig. 5). Data in Fig. 4 B imply interaction with Y499
diminishes nucleotide-induced extinction enhancement in
W506 (extinction enhancement in W506 is larger without
Y499). Data in Fig. 5 imply interaction with Y499 eliminates
nucleotide-induced ﬂuorescence enhancement in W506
(ﬂuorescence enhancement in W506 is absent in the presence
of Y499). These effects could be one in the same if di-
minished extinction is solely responsible for the lack of
ﬂuorescence enhancement in W5061 or could be indepen-
dent with an excited state interaction between Y499 and
W506 also needed to fully nullify enhancement. The latter is
more likely because W506 (by Fig. 4 B) is nucleotide
sensitive and an enhancement detectable with absorption is
normally detectable by ﬂuorescence. Since no ﬂuorescence
enhancement is observed (by Fig. 5), Y499 is probably
quenching W506 by an excited state process. The latter is
supported by the signiﬁcantly longer W506 ﬂuorescence
lifetimes in W5061(Y499F) compared to W5061 for the
M* and M** conformations (Table 4). We predicted the
interaction between the skeletal myosin homologs of Y499
and W506, however, ﬂuorescence enhancement in smA and
skeletal myosin is obviously different and there are several
possible explanations. For instance, i), the Y499/W506
ground state interaction enhancement is identical for both
isoforms but Y499 is a suppressor (smA) or enhancer
(skeletal) of W506 emission, ii), only differences in the
Y499/W506 ground state interaction enhancement between
isoforms give rise to the different nucleotide sensitivity, or
iii), some combination of i and ii.
Reduced nucleotide-induced tryptophan ﬂuorescence en-
hancement in the W506F construct compared to WT is most
likely from the structural perturbation introduced by muta-
tion makingW506F unable to form the M** conformation as
shown previously for the homologous mutation in the Dc
myosin II motor domain (70). Both W5061(Y499F) and
W506F constructs have elevated Mg21 and Ca21 ATPases
and negligible K1EDTA-ATPases compared to W5061 and
WT. W5061(Y499F) binds actin less strongly in the Apo
conformation compared to W5061 and WT and it is not
actin activated. All changes in W5061(Y499F) and W506F
functionality parallel changes in the smB isoform for point
mutations in residues colocalized with Y499 (46).
We have shown that the loop 1 deletion distinguishing
smA and smB isoforms introduces changes to myosin trans-
duction that are difﬁcult to foresee by intuition. This ap-
plication demonstrates difﬁculties facing proactive protein
engineering when apparently minor sequence changes, rea-
sonably assumed to affect product release, in practice have
wider and unanticipated effects. Protein modularity is a
concept whereby function is deﬁned by standard inter-
changeable modules performing speciﬁc tasks in the protein.
The notion was applied years ago to myosin with the dis-
covery of conserved proteolysis products suggesting they
constitute functional domains (71,72). Functional domains
deﬁned by proteolysis proved to be of limited practical value
in myosin but the idea remains inviting for use in new
applications in protein engineering. Modularity mitigates the
effect of a sequence change designed for one purpose
spilling over into another area of protein function. This result
would argue loop 1 is the interface between modules causing
effects that purposefully spill over module boundaries.
CONCLUSION
Smooth muscle myosin has isoforms partitioning prefer-
entially into tonic or phasic muscle types. Tonic muscle
preferentially contains the smA isoform lacking a seven-
amino-acid insert in the active site at loop 1. Phasic muscle
preferentially contains the smB isoform containing the loop
1 insert. Homology modeling of smA and smB sequences
with available myosin crystal structures indicates reduced
loop 1 structural heterogeneity, implying reduced dynamic
ﬂexibility, in the shorter form. Nucleotide-induced ﬂuores-
cence intensity increase in the highly conserved W506
occurs in all myosin isoforms previously tested implying it
results from common origin within the conserved motor
core. WT-smA has nucleotide-induced tryptophan ﬂuores-
cence enhancement like other myosin isoforms but we
showed with site-directed mutagenesis that the NST is
probably not W506. Nonetheless, the additional Y499F
substitution partially restores nucleotide sensitivity in W506
demonstrating Y499’s predicted role as a NST facilitator.
These experimental results suggest that smA and smB myosin
isoforms have different inﬂuence propagating pathways
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emanating from the active site. The seven-amino-acid
deletion from loop 1, suggested previously to alter ATPase
kinetics by interfering with ADP release, also affects distant
sites in the protein by measurably altering their communi-
cation link to the active site.
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